HC Wainwright Issues Negative Outlook for TRDA Earnings

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Equities researchers at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for Entrada Therapeutics in a research note issued to investors on Monday, August 10th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($1.18) per share for the quarter, down from their previous forecast of ($1.17). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is ($4.07) per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q4 2026 earnings at ($1.04) EPS, FY2026 earnings at ($4.19) EPS and FY2027 earnings at ($3.13) EPS.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.

Several other brokerages have also issued reports on TRDA. Roth Capital set a $10.00 price target on Entrada Therapeutics in a research note on Friday, May 8th. Guggenheim lowered their price objective on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, June 8th. Finally, Weiss Ratings downgraded shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $17.50.

Entrada Therapeutics Price Performance

Shares of Entrada Therapeutics stock opened at $7.04 on Wednesday. The stock’s 50-day moving average is $6.87 and its 200 day moving average is $9.65. Entrada Therapeutics has a one year low of $5.02 and a one year high of $16.45. The firm has a market cap of $274.14 million, a price-to-earnings ratio of -1.78 and a beta of -0.26.

Hedge Funds Weigh In On Entrada Therapeutics

Large investors have recently modified their holdings of the company. State of Wyoming bought a new stake in Entrada Therapeutics during the 2nd quarter valued at $37,000. Russell Investments Group Ltd. lifted its stake in shares of Entrada Therapeutics by 72.7% in the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after buying an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP bought a new position in shares of Entrada Therapeutics in the second quarter valued at $68,000. Jain Global LLC acquired a new position in shares of Entrada Therapeutics during the third quarter valued at about $69,000. Finally, IHT Wealth Management LLC acquired a new position in shares of Entrada Therapeutics during the second quarter valued at about $72,000. 86.39% of the stock is currently owned by institutional investors.

Insider Activity at Entrada Therapeutics

In related news, Director Kush Parmar sold 92,444 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $7.00, for a total transaction of $647,108.00. Following the transaction, the director directly owned 2,691,337 shares of the company’s stock, valued at approximately $18,839,359. This represents a 3.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bernhardt G. Zeiher purchased 5,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $5.86 per share, for a total transaction of $29,300.00. Following the acquisition, the director owned 5,000 shares of the company’s stock, valued at approximately $29,300. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold 451,014 shares of company stock valued at $3,124,822 in the last three months. Corporate insiders own 9.49% of the company’s stock.

Entrada Therapeutics News Roundup

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Institutional ownership remains high at approximately 86.4%. BlackRock opened a position worth about $19.0 million, while Millennium Management, Citadel Advisors and Qube Research increased their holdings. These purchases may provide some underlying demand for TRDA shares.
• Positive Sentiment: Analyst coverage remains mixed but includes three Buy ratings. The average price target is reported at $17.50, well above recent trading levels, although HC Wainwright downgraded the stock to Neutral and Guggenheim lowered its target to $17.00. Entrada Therapeutics analyst and stock information
• Neutral Sentiment: Reported short interest was zero shares, with a zero-day days-to-cover ratio. Because the data also shows an “NaN” change from the prior period, it offers little reliable insight into current short-selling pressure.
• Negative Sentiment: Major shareholder Ventures V. L.P. 5Am sold a combined 62,811 shares on August 6 and 7 for approximately $431,829, reducing its position by about 2.2%. The shareholder still owns more than 2.7 million shares, so the sales represent a modest reduction rather than a full exit. SEC filing on Ventures V. L.P. 5Am share sales
• Negative Sentiment: Director Kush Parmar sold 155,255 shares across three transactions from August 6 through August 10 for roughly $1.08 million, cutting his holdings by approximately 5.5%. Repeated insider selling can weigh on sentiment, even though he continues to hold a substantial stake. SEC filing on Kush Parmar share sales
• Negative Sentiment: Entrada’s latest quarterly results missed expectations: adjusted loss per share was $1.01 versus an expected $0.97 loss, while revenue of $0.90 million fell short of the $2.32 million consensus. The clinical-stage biotechnology company is expected to remain unprofitable, with analysts forecasting a full-year loss of approximately $4.07 per share.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.